Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4221 Assessing the frequency of type I gastric neuroendocrine neoplasms in autoimmune atrophic gastritis: A multi-center study in Italy

Introduction: In autoimmune atrophic gastritis (AAG), mucosa morpho-functional changes lead to hypo-achlorhydria, hypergastrinemia, and enterochromaffin-like (ECL) cells proliferation, escalating the risk of type I gastric neuroendocrine neoplasms (gNENs). Longitudinal studies on the AAG-gNENs association are scanty.

Conference:

Presenting Author: Gallo C

Authors: Massironi S, Gallo C, Lahner E, Sciola V, Cavalcoli F,

Keywords: neuroendocrine tumor, atrophic gastritis, autoimmune gastritis, gastrin,

#2145 Thrombotic Risk in Gastroenteropancreatic Neuroendocrine Tumors: A Single Centre Experience

Introduction: Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of neoplasms associated with paraneoplastic syndromes. Venous thromboembolism (VTE) is a frequent complication in neoplastic patients and it is associated with increased morbidity and mortality. To date, there have been no specific studies in NEN, except for glucagon-secreting tumors

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Cavalcoli F

Authors: Cavalcoli F, Rossi R, Artoni A, Sciola V, Zilli A,

Keywords: GEP-NEt, paraneoplastic syndromes, Venous thromboembolism,

#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Massironi S

Authors: Massironi S, Conte D, Sciola V, Spampatti M, Rossi R,

Keywords: gastroenteropancreatic neuroendocrine tumors, carcinoids, pancreatic endocrine tumors, chromogranin A, somatostatin analogues,